PUBLISHER: KBV Research | PRODUCT CODE: 1395855
PUBLISHER: KBV Research | PRODUCT CODE: 1395855
The Europe Ureteral Stents Market would witness market growth of 6.2% CAGR during the forecast period (2023-2030). In the year 2020, the Europe market's volume surged to 2,133.8 thousand units, showcasing a growth of 5.9% (2019-2022).
These stents are commonly used to address urinary tract obstructions, providing a temporary or permanent solution to restore normal urine flow. Conditions such as kidney stones, tumors, or strictures can lead to blockages in the ureter, necessitating the placement of stents to ensure unobstructed urine drainage. After urological procedures, such as ureteroscopy or surgeries to address tumors, the stents are often employed to promote healing and prevent complications. By serving as conduits for urinary flow, these stents ensure optimal recovery and reduce the risk of postoperative complications.
Moreover, these stents play a crucial role in managing kidney stones. By facilitating the passage of small stone fragments and preventing blockages, stents offer relief to individuals experiencing pain and discomfort associated with kidney stones. Kidney stones can lead to significant pain and discomfort, and these stents are employed as part of the treatment strategy to address these symptoms and aid in the passage of stone fragments. The presence of a stent helps prevent the stone fragments from causing a complete blockage in the ureter, easing the flow of urine and minimizing the associated pain. This facilitates the gradual passage of stones through the urinary tract, promoting a more comfortable and less symptomatic experience for the patient.
As per the data from the Office for National Statistics of the United Kingdom, the Census results 2021 show that the population of England and Wales has continued to age and that there are now more people than ever in older age categories. More than 11 million persons, or 18.6% of the entire population, were 65 years of age or older, up from 16.4% in the 2011 census. In England and Wales, the median (average) age increased from 39 to 40 years between 2011 and 2021, indicating the changing demographics of the population. Therefore, an aging population in many countries of Europe is expected to boost the demand for these stents in the region as older people are more susceptible to developing urological disorders.
The Germany market dominated the Europe Ureteral Stents Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $55.5 million by 2030. The UK market is exhibiting a CAGR of 5.2% during (2023 - 2030). Additionally, The France market would experience a CAGR of 7% during (2023 - 2030).
Based on End User, the market is segmented into Hospitals, and Ambulatory Surgical Centers (ASCS) & Clinics. Based on Material, the market is segmented into Metallic Stents and Polymer Stents (Silicone Stents, Hybrid Stents, and Polyurethane Stents). Based on Product, the market is segmented into Double Pigtail Stent, Open/Closed Pigtail Stent, and Multiloop Stents. Based on Application, the market is segmented into Kidney Stones, Kidney Transplantation, Urinary Incontinence, Tumors, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, B. Braun Melsungen AG, Coloplast Group, Medline Industries, Inc., Allium Ltd, Cook Medical, Inc. (Cook Group), Pnn Medical A/S, Teleflex, Inc., Olympus Corporation and Becton, Dickinson, and Company
Market Segments covered in the Report:
By End User (Volume, Thousand Units, Revenue, USD Million, 2019-30)
By Material (Volume, Thousand Units, Revenue, USD Million, 2019-30)
By Product (Volume, Thousand Units, Revenue, USD Million, 2019-30)
By Application (Volume, Thousand Units, Revenue, USD Million, 2019-30)
By Country (Volume, Thousand Units, Revenue, USD Million, 2019-30)
Companies Profiled
Unique Offerings from KBV Research